Top

Published in:

Open Access 01-11-2019 | Arterial Occlusive Disease | Review

The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification

Authors: Miguel Carracedo, Gonzalo Artiach, Hildur Arnardottir, Magnus Bäck

Published in: Seminars in Immunopathology | Issue 6/2019

Abstract

Omega-3 fatty acids serve as the substrate for the formation of a group of lipid mediators that mediate the resolution of inflammation. The cardiovascular inflammatory response in atherosclerosis and vascular injury is characterized by a failure in the resolution of inflammation, resulting in a chronic inflammatory response. The proresolving lipid mediator resolvin E1 (RvE1) is formed by enzymatic conversion of the omega-3 fatty acid eicosapentaenoic acid (EPA), and signals resolution of inflammation through its receptor ChemR23. Importantly, the resolution of cardiovascular inflammation is an active, multifactorial process that involves modulation of the immune response, direct actions on the vascular wall, as well as close interactions between macrophages and vascular smooth muscle cells. Promoting anti-atherogenic signalling through the stimulation of endogenous resolution of inflammation pathways may provide a novel therapeutic strategy in cardiovascular prevention.

Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347):317–325. https://doi.org/10.1038/nature10146 CrossRefPubMed

Bäck M, Yurdagul A Jr, Tabas I, Oorni K, Kovanen PT (2019) Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol 16(7):389–406. https://doi.org/10.1038/s41569-019-0169-2 CrossRefPubMedPubMedCentral

Tunon J, Badimon L, Bochaton-Piallat ML, Cariou B, Daemen MJ, Egido J, Evans PC, Hoefer IE, Ketelhuth DFJ, Lutgens E, Matter CM, Monaco C, Steffens S, Stroes E, Vindis C, Weber C, Bäck M (2019) Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovasc Res 115(1):10–19. https://doi.org/10.1093/cvr/cvy293 CrossRefPubMed

Bäck M, Hansson GK (2015) Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 12(4):199–211. https://doi.org/10.1038/nrcardio.2015.5 CrossRefPubMed

Ridker PM, Everett BM, Thuren T, JG MF, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, Group CT (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131. https://doi.org/10.1056/NEJMoa1707914 CrossRefPubMed

Bäck M (2008) Inflammatory signaling through leukotriene receptors in atherosclerosis. Curr Atheroscler Rep 10(3):244–251CrossRefPubMed

Petri MH, Laguna-Fernandez A, Arnardottir H, Wheelock CE, Perretti M, Hansson GK, Bäck M (2017) Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E(-/-) mice. Br J Pharmacol 174(22):4043–4054. https://doi.org/10.1111/bph.13707 CrossRefPubMedPubMedCentral

Labat C, Temmar M, Nagy E, Bean K, Brink C, Benetos A, Bäck M (2013) Inflammatory mediators in saliva associated with arterial stiffness and subclinical atherosclerosis. J Hypertens 31(11):2251–2258; discussion 2258. https://doi.org/10.1097/HJH.0b013e328363dccc CrossRefPubMedPubMedCentral

Fredman G, Ozcan L, Spolitu S, Hellmann J, Spite M, Backs J, Tabas I (2014) Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc Natl Acad Sci U S A 111(40):14530–14535. https://doi.org/10.1073/pnas.1410851111 CrossRefPubMedPubMedCentral

10.

Petri MH, Laguna-Fernandez A, Gonzalez-Diez M, Paulsson-Berne G, Hansson GK, Bäck M (2015) The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability. Cardiovasc Res 105(1):65–74. https://doi.org/10.1093/cvr/cvu224 CrossRefPubMed

11.

Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AH, Pande R, Creager MA, Serhan CN, Conte MS (2010) Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol 177(4):2116–2123. https://doi.org/10.2353/ajpath.2010.091082 CrossRefPubMedPubMedCentral

12.

Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510(7503):92–101. https://doi.org/10.1038/nature13479 CrossRefPubMedPubMedCentral

13.

Fredman G, Hellmann J, Proto JD, Kuriakose G, Colas RA, Dorweiler B, Connolly ES, Solomon R, Jones DM, Heyer EJ, Spite M, Tabas I (2016) An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat Commun 7:12859. https://doi.org/10.1038/ncomms12859 CrossRefPubMedPubMedCentral

14.

Thul S, Labat C, Temmar M, Benetos A, Bäck M (2017) Low salivary resolvin D1 to leukotriene B4 ratio predicts carotid intima media thickness: a novel biomarker of non-resolving vascular inflammation. Eur J Prev Cardiol 24(9):903–906. https://doi.org/10.1177/2047487317694464 CrossRefPubMed

15.

Werz O, Gerstmeier J, Libreros S, De la Rosa X, Werner M, Norris PC, Chiang N, Serhan CN (2018) Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat Commun 9(1):59. https://doi.org/10.1038/s41467-017-02538-5 CrossRefPubMedPubMedCentral

16.

Chiang N, Fredman G, Backhed F, Oh SF, Vickery T, Schmidt BA, Serhan CN (2012) Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484(7395):524–528. https://doi.org/10.1038/nature11042 CrossRefPubMedPubMedCentral

17.

Dyerberg J, Bang HO (1979) Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 2(8140):433–435. https://doi.org/10.1016/s0140-6736(79)91490-9 CrossRefPubMed

18.

Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196(8):1025–1037. https://doi.org/10.1084/jem.20020760 CrossRefPubMedPubMedCentral

19.

Bäck M, Hansson GK (2019) Omega-3 fatty acids, cardiovascular risk, and the resolution of inflammation. FASEB J 33(2):1536–1539. https://doi.org/10.1096/fj.201802445R CrossRefPubMed

20.

Fredman G, Tabas I (2017) Boosting inflammation resolution in atherosclerosis: the next frontier for therapy. Am J Pathol 187(6):1211–1221. https://doi.org/10.1016/j.ajpath.2017.01.018 CrossRefPubMedPubMedCentral

21.

Hamilton JA, Hasturk H, Kantarci A, Serhan CN, Van Dyke T (2017) Atherosclerosis, periodontal disease, and treatment with Resolvins. Curr Atheroscler Rep 19(12):57. https://doi.org/10.1007/s11883-017-0696-4 CrossRefPubMed

22.

Elajami TK, Colas RA, Dalli J, Chiang N, Serhan CN, Welty FK (2016) Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J 30(8):2792–2801. https://doi.org/10.1096/fj.201500155R CrossRefPubMedPubMedCentral

23.

Bäck M (2017) Omega-3 fatty acids in atherosclerosis and coronary artery disease. Future Sci OA 3(4):FSO236. https://doi.org/10.4155/fsoa-2017-0067 CrossRefPubMedPubMedCentral

24.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, Investigators R-I (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380(1):11–22. https://doi.org/10.1056/NEJMoa1812792 CrossRefPubMed

25.

Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Jelis Investigators J (2008) Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200(1):135–140. https://doi.org/10.1016/j.atherosclerosis.2008.06.003 CrossRefPubMed

26.

Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN (2007) Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178(6):3912–3917. https://doi.org/10.4049/jimmunol.178.6.3912 CrossRefPubMed

27.

Pirault J, Back M (2018) Lipoxin and resolvin receptors transducing the resolution of inflammation in cardiovascular disease. Front Pharmacol 9:1273. https://doi.org/10.3389/fphar.2018.01273 CrossRefPubMedPubMedCentral

28.

Sima C, Montero E, Nguyen D, Freire M, Norris P, Serhan CN, Van Dyke TE (2017) ERV1 overexpression in myeloid cells protects against high fat diet induced obesity and glucose intolerance. Sci Rep 7(1):12848. https://doi.org/10.1038/s41598-017-13185-7 CrossRefPubMedPubMedCentral

29.

Sato T, Horikawa M, Takei S, Yamazaki F, Ito TK, Kondo T, Sakurai T, Kahyo T, Ikegami K, Sato S, Sato R, Jinno Y, Kawano H, Naoe S, Arita M, Kashiwagi Y, Setou M (2019) Preferential incorporation of administered eicosapentaenoic acid into thin-cap atherosclerotic plaques. Arterioscler Thromb Vasc Biol 39(9):1802–1816. https://doi.org/10.1161/ATVBAHA.119.313093 CrossRefPubMed

30.

Van Noolen L, Bäck M, Arnaud C, Rey A, Petri MH, Levy P, Faure P, Stanke-Labesque F (2014) Docosahexaenoic acid supplementation modifies fatty acid incorporation in tissues and prevents hypoxia induced-atherosclerosis progression in apolipoprotein-E deficient mice. Prostaglandins Leukot Essent Fatty Acids 91(4):111–117. https://doi.org/10.1016/j.plefa.2014.07.016 CrossRef

31.

Laguna-Fernandez A, Checa A, Carracedo M, Artiach G, Petri MH, Baumgartner R, Forteza MJ, Jiang X, Andonova T, Walker ME, Dalli J, Arnardottir H, Gistera A, Thul S, Wheelock CE, Paulsson-Berne G, Ketelhuth DFJ, Hansson GK, Bäck M (2018) ERV1/ChemR23 signaling protects against atherosclerosis by modifying oxidized low-density lipoprotein uptake and phagocytosis in macrophages. Circulation 138(16):1693–1705. https://doi.org/10.1161/CIRCULATIONAHA.117.032801 CrossRefPubMedPubMedCentral

32.

Stanke-Labesque F, Pepin JL, Gautier-Veyret E, Levy P, Bäck M (2014) Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis. Cardiovasc Res 101(2):187–193. https://doi.org/10.1093/cvr/cvt247 CrossRefPubMed

33.

Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M (2004) Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350(1):29–37. https://doi.org/10.1056/NEJMoa025079 CrossRefPubMed

34.

Schwab JM, Chiang N, Arita M, Serhan CN (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447(7146):869–874. https://doi.org/10.1038/nature05877 CrossRefPubMedPubMedCentral

35.

Thorp E, Tabas I (2009) Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol 86(5):1089–1095. https://doi.org/10.1189/jlb.0209115 CrossRefPubMedPubMedCentral

36.

Tajbakhsh A, Rezaee M, Kovanen PT, Sahebkar A (2018) Efferocytosis in atherosclerotic lesions: malfunctioning regulatory pathways and control mechanisms. Pharmacol Ther 188:12–25. https://doi.org/10.1016/j.pharmthera.2018.02.003 CrossRefPubMed

37.

Tabas I (2010) Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 10(1):36–46. https://doi.org/10.1038/nri2675 CrossRefPubMed

38.

Yurdagul A Jr, Doran AC, Cai B, Fredman G, Tabas IA (2017) Mechanisms and consequences of defective efferocytosis in atherosclerosis. Front Cardiovasc Med 4:86. https://doi.org/10.3389/fcvm.2017.00086 CrossRefPubMed

39.

Arnardottir H, Orr SK, Dalli J, Serhan CN (2016) Human milk proresolving mediators stimulate resolution of acute inflammation. Mucosal Immunol 9(3):757–766. https://doi.org/10.1038/mi.2015.99 CrossRefPubMed

40.

Pentikainen MO, Oorni K, Ala-Korpela M, Kovanen PT (2000) Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 247(3):359–370CrossRefPubMed

41.

Schrijvers DM, De Meyer GR, Herman AG, Martinet W (2007) Phagocytosis in atherosclerosis: molecular mechanisms and implications for plaque progression and stability. Cardiovasc Res 73(3):470–480. https://doi.org/10.1016/j.cardiores.2006.09.005 CrossRefPubMed

42.

Delbosc S, Bayles RG, Laschet J, Ollivier V, Ho-Tin-Noe B, Touat Z, Deschildre C, Morvan M, Louedec L, Gouya L, Guedj K, Nicoletti A, Michel JB (2017) Erythrocyte efferocytosis by the arterial wall promotes oxidation in early-stage atheroma in humans. Front Cardiovasc Med 4:43. https://doi.org/10.3389/fcvm.2017.00043 CrossRefPubMedPubMedCentral

43.

Salic K, Morrison MC, Verschuren L, Wielinga PY, Wu L, Kleemann R, Gjorstrup P, Kooistra T (2016) Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 250:158–165. https://doi.org/10.1016/j.atherosclerosis.2016.05.001 CrossRefPubMed

44.

Hasturk H, Abdallah R, Kantarci A, Nguyen D, Giordano N, Hamilton J, Van Dyke TE (2015) Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler Thromb Vasc Biol 35(5):1123–1133. https://doi.org/10.1161/ATVBAHA.115.305324 CrossRefPubMedPubMedCentral

45.

Viola JR, Lemnitzer P, Jansen Y, Csaba G, Winter C, Neideck C, Silvestre-Roig C, Dittmar G, Doring Y, Drechsler M, Weber C, Zimmer R, Cenac N, Soehnlein O (2016) Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ Res 119(9):1030–1038. https://doi.org/10.1161/CIRCRESAHA.116.309492 CrossRefPubMed

46.

van der Vorst EPC, Mandl M, Muller M, Neideck C, Jansen Y, Hristov M, Gencer S, Peters LJF, Meiler S, Feld M, Geiselhoringer AL, de Jong RJ, Ohnmacht C, Noels H, Soehnlein O, Drechsler M, Weber C, Doring Y (2019) Hematopoietic ChemR23 (chemerin receptor 23) fuels atherosclerosis by sustaining an M1 macrophage-phenotype and guidance of plasmacytoid dendritic cells to murine lesions-brief report. Arterioscler Thromb Vasc Biol 39(4):685–693. https://doi.org/10.1161/ATVBAHA.119.312386 CrossRefPubMed

47.

Bäck M, Powell WS, Dahlen SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE (2014) Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR review 7. Br J Pharmacol 171(15):3551–3574. https://doi.org/10.1111/bph.12665 CrossRefPubMedPubMedCentral

48.

van der Vorst EPC, Peters LJF, Muller M, Gencer S, Yan Y, Weber C, Doring Y (2019) G-protein coupled receptor targeting on myeloid cells in atherosclerosis. Front Pharmacol 10:531. https://doi.org/10.3389/fphar.2019.00531 CrossRefPubMedPubMedCentral

49.

Sato K, Yoshizawa H, Seki T, Shirai R, Yamashita T, Okano T, Shibata K, Wakamatsu MJ, Mori Y, Morita T, Matsuyama TA, Ishibashi-Ueda H, Hirano T, Watanabe T (2019) Chemerin-9, a potent agonist of chemerin receptor (ChemR23), prevents atherogenesis. Clin Sci (Lond) 133(16):1779–1796. https://doi.org/10.1042/CS20190336 CrossRef

50.

Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML (2018) Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc Res 114(4):540–550. https://doi.org/10.1093/cvr/cvy022 CrossRefPubMedPubMedCentral

51.

Wadey K, Lopes J, Bendeck M, George S (2018) Role of smooth muscle cells in coronary artery bypass grafting failure. Cardiovasc Res 114(4):601–610. https://doi.org/10.1093/cvr/cvy021 CrossRefPubMedPubMedCentral

52.

Carracedo M, Artiach G, Witasp A, Claria J, Carlstrom M, Laguna-Fernandez A, Stenvinkel P, Bäck M (2019) The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification. Cardiovasc Res 115(10):1557-1566. https://doi.org/10.1093/cvr/cvy316 CrossRef

53.

Lacolley P, Regnault V, Segers P, Laurent S (2017) Vascular smooth muscle cells and arterial stiffening: relevance in development, aging, and disease. Physiol Rev 97(4):1555–1617. https://doi.org/10.1152/physrev.00003.2017 CrossRefPubMed

54.

Wu B, Mottola G, Schaller M, Upchurch GR Jr, Conte MS (2017) Resolution of vascular injury: specialized lipid mediators and their evolving therapeutic implications. Mol Asp Med 58:72–82. https://doi.org/10.1016/j.mam.2017.07.005 CrossRef

55.

Delbosc S, Glorian M, Le Port AS, Bereziat G, Andreani M, Limon I (2008) The benefit of docosahexanoic acid on the migration of vascular smooth muscle cells is partially dependent on notch regulation of MMP-2/−9. Am J Pathol 172(5):1430–1440. https://doi.org/10.2353/ajpath.2008.070951 CrossRefPubMedPubMedCentral

56.

Pope NH, Salmon M, Davis JP, Chatterjee A, Su G, Conte MS, Ailawadi G, Upchurch GR Jr (2016) D-series resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization. FASEB J 30(12):4192–4201. https://doi.org/10.1096/fj.201600144RR CrossRefPubMedPubMedCentral

57.

Norris PC, Arnardottir H, Sanger JM, Fichtner D, Keyes GS, Serhan CN (2018) Resolvin D3 multi-level proresolving actions are host protective during infection. Prostaglandins Leukot Essent Fatty Acids 138:81–89. https://doi.org/10.1016/j.plefa.2016.01.001 CrossRefPubMed

58.

Mottola G, Chatterjee A, Wu B, Chen M, Conte MS (2017) Aspirin-triggered resolvin D1 attenuates PDGF-induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate/protein kinase a (cAMP/PKA) pathway. PLoS One 12(3):e0174936. https://doi.org/10.1371/journal.pone.0174936 CrossRefPubMedPubMedCentral

59.

Hiram R, Rizcallah E, Marouan S, Sirois C, Sirois M, Morin C, Fortin S, Rousseau E (2015) Resolvin E1 normalizes contractility, Ca2+ sensitivity and smooth muscle cell migration rate in TNF-alpha- and IL-6-pretreated human pulmonary arteries. Am J Physiol Lung Cell Mol Physiol 309(8):L776–L788. https://doi.org/10.1152/ajplung.00177.2015 CrossRefPubMed

60.

Liu G, Gong Y, Zhang R, Piao L, Li X, Liu Q, Yan S, Shen Y, Guo S, Zhu M, Yin H, Funk CD, Zhang J, Yu Y (2018) Resolvin E1 attenuates injury-induced vascular neointimal formation by inhibition of inflammatory responses and vascular smooth muscle cell migration. FASEB J 32(10):5413–5425. https://doi.org/10.1096/fj.201800173R CrossRefPubMed

61.

Miyahara T, Runge S, Chatterjee A, Chen M, Mottola G, Fitzgerald JM, Serhan CN, Conte MS (2013) D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J 27(6):2220–2232. https://doi.org/10.1096/fj.12-225615 CrossRefPubMedPubMedCentral

62.

Akagi D, Chen M, Toy R, Chatterjee A, Conte MS (2015) Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J 29(6):2504–2513. https://doi.org/10.1096/fj.14-265363 CrossRefPubMedPubMedCentral

63.

Artiach G, Carracedo M, Clària J, Laguna-Fernandez A, Bäck M (2018) Opposing effects on vascular smooth muscle cell proliferation and macrophage-induced inflammation reveal a protective role for the proresolving lipid mediator receptor ChemR23 in intimal hyperplasia. Front Pharmacol 9:1327. https://doi.org/10.3389/fphar.2018.01327 CrossRefPubMedPubMedCentral

64.

Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan CM (2018) Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc Res 114(4):590–600. https://doi.org/10.1093/cvr/cvy010 CrossRefPubMedPubMedCentral

65.

Dweck MR, Aikawa E, Newby DE, Tarkin JM, Rudd JH, Narula J, Fayad ZA (2016) Noninvasive molecular imaging of disease activity in atherosclerosis. Circ Res 119(2):330–340. https://doi.org/10.1161/CIRCRESAHA.116.307971 CrossRefPubMedPubMedCentral

66.

Sekikawa A, Miura K, Lee S, Fujiyoshi A, Edmundowicz D, Kadowaki T, Evans RW, Kadowaki S, Sutton-Tyrrell K, Okamura T, Bertolet M, Masaki KH, Nakamura Y, Barinas-Mitchell EJM, Willcox BJ, Kadota A, Seto TB, Maegawa H, Kuller LH, Ueshima H (2014) Long-chain n-3 polyunsaturated fatty acids and incidence rate of coronary artery calcification in Japanese in Japan and United States whites – population-based prospective cohort study. Heart 100(7):569–573. https://doi.org/10.1136/heartjnl-2013-304421 CrossRefPubMed

67.

Sekikawa A, Mahajan H, Kadowaki S, Hisamatsu T, Miyagawa N, Fujiyoshi A, Kadota A, Maegawa H, Murata K, Miura K, Edmundowicz D, Ueshima H (2019) Association of blood levels of marine omega-3 fatty acids with coronary calcification and calcium density in Japanese men. Eur J Clin Nutr 73(5):783–792. https://doi.org/10.1038/s41430-018-0242-7 CrossRefPubMed

68.

Kanai S, Uto K, Honda K, Hagiwara N, Oda H (2011) Eicosapentaenoic acid reduces warfarin-induced arterial calcification in rats. Atherosclerosis 215(1):43–51. https://doi.org/10.1016/j.atherosclerosis.2010.12.001 CrossRefPubMed

69.

Nakamura K, Miura D, Saito Y, Yunoki K, Koyama Y, Satoh M, Kondo M, Osawa K, Hatipoglu OF, Miyoshi T, Yoshida M, Morita H, Ito H (2017) Eicosapentaenoic acid prevents arterial calcification in klotho mutant mice. PLoS One 12(8):e0181009. https://doi.org/10.1371/journal.pone.0181009 CrossRefPubMedPubMedCentral

70.

Abedin M, Lim J, Tang TB, Park D, Demer LL, Tintut Y (2006) N-3 fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor-gamma pathways. Circ Res 98(6):727–729. https://doi.org/10.1161/01.RES.0000216009.68958.e6 CrossRefPubMed

71.

Saito Y, Nakamura K, Miura D, Yunoki K, Miyoshi T, Yoshida M, Kawakita N, Kimura T, Kondo M, Sarashina T, Akagi S, Watanabe A, Nishii N, Morita H, Ito H (2017) Suppression of Wnt signaling and osteogenic changes in vascular smooth muscle cells by eicosapentaenoic acid. Nutrients 9(8). https://doi.org/10.3390/nu9080858 CrossRefPubMedCentral

72.

Carracedo M, Witasp A, Qureshi AR, Laguna-Fernandez A, Brismar T, Stenvinkel P, Bäck M (2019) Chemerin inhibits vascular calcification through ChemR23 and is associated with lower coronary calcium in chronic kidney disease. J Intern Med. https://doi.org/10.1111/joim.12940 CrossRefPubMedPubMedCentral

73.

Conte MS, Desai TA, Wu B, Schaller M, Werlin E (2018) Pro-resolving lipid mediators in vascular disease. J Clin Invest 128(9):3727–3735. https://doi.org/10.1172/JCI97947 CrossRefPubMedPubMedCentral

74.

Shah PK (2003) Inflammation, neointimal hyperplasia, and restenosis: as the leukocytes roll, the arteries thicken. Circulation 107(17):2175–2177. https://doi.org/10.1161/01.CIR.0000069943.41206.BD CrossRefPubMed

75.

Makino Y, Miyahara T, Nitta J, Miyahara K, Seo A, Kimura M, Suhara M, Akai A, Akagi D, Yamamoto K, Hoshina K (2019) Proresolving lipid mediators resolvin D1 and protectin D1 isomer attenuate neointimal hyperplasia in the rat carotid artery balloon injury model. J Surg Res 233:104–110. https://doi.org/10.1016/j.jss.2018.07.049 CrossRefPubMed

76.

Wu B, Werlin EC, Chen M, Mottola G, Chatterjee A, Lance KD, Bernards DA, Sansbury BE, Spite M, Desai TA, Conte MS (2018) Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rabbit vein graft model. J Vasc Surg 68(6S):188S-200S.e184. https://doi.org/10.1016/j.jvs.2018.05.206 CrossRef

77.

Wu B, Mottola G, Chatterjee A, Lance KD, Chen M, Siguenza IO, Desai TA, Conte MS (2017) Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury. J Vasc Surg 65(1):207-217.e203. https://doi.org/10.1016/j.jvs.2016.01.030 CrossRef

Title: The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification
Authors: Miguel Carracedo
Gonzalo Artiach
Hildur Arnardottir
Magnus Bäck
Publication date: 01-11-2019
Publisher: Springer Berlin Heidelberg
Keyword: Arterial Occlusive Disease
Published in: Seminars in Immunopathology / Issue 6/2019
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-019-00767-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2019

Resolution of inflammation during multiple sclerosis

Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease)

Resolution of inflammation in arthritis

Resolution in bullous pemphigoid

Resolution of allergic asthma

Resolution of acute intestinal graft-versus-host disease

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage